XOMA

Yahoo Finance • yesterday

Mural Oncology Shareholders To Receive $2.035 Cash Per Share In XOMA Royalty Acquisition

(RTTNews) - Mural Oncology plc (MURA) on Wednesday announced that the final cash consideration payable to its shareholders upon closing of its acquisition by XOMA Royalty Corporation (XOMA) has been set at $2.035 per share in cash. The de... Full story

Yahoo Finance • 3 days ago

Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA Royalty

WALTHAM, Mass. and DUBLIN, Ireland, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA) (“Mural”) announces that, in accordance with the terms of the transaction agreement between XOMA Royalty Corporation (Nasdaq: XOMA) (... Full story

Yahoo Finance • 8 days ago

XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.

EMERYVILLE, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA) today announced it has successfully completed its previously announced acquisition of all the outstanding common shares of LAV... Full story

Yahoo Finance • 17 days ago

XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements

Business development: Secures royalty economic interests in two early stage partnered assets through XOMA Royalty’s announced expected acquisition of LAVA Therapeutics. Company acquisitions: •Completed XOMA Royalty’s acquisitions of Turns... Full story

Yahoo Finance • 19 days ago

LAVA Therapeutics N.V. Shareholders are Reminded to Tender Shares for XOMA Royalty Transaction Before November 12, 2025 Deadline

UTRECHT, The Netherlands and PHILADELPHIA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (“LAVA”) (NASDAQ: LVTX) today announced a reminder to LAVA shareholders related to the proposed transaction with XOMA Royalty Corporation... Full story

Yahoo Finance • last month

Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION WALTHAM, Mass. and DUBLIN, Ireland,... Full story

Yahoo Finance • last month

XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement

- Amendment includes finalized cash amount and updated CVR terms for tender offer - LAVA announces new date for extraordinary general meeting of shareholders EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Penn., Oct.... Full story

Yahoo Finance • 2 months ago

XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.

EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Oct. 02, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (NASDAQ: XOMA) and LAVA Therapeutics N.V. (“LAVA”) (Nasdaq: LVTX) today announced the extension... Full story

Yahoo Finance • 2 months ago

Mural Oncology Announces Commencement of Mailing of Definitive Proxy Statement and Details of Scheme Meeting and Extraordinary General Meeting

WALTHAM, Mass. and DUBLIN, Ireland, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (Nasdaq: MURA) (“Mural”), a clinical-stage immuno-oncology company, today announces for the purposes of the Irish Takeover Panel Act, 1997, Takeov... Full story

Yahoo Finance • 2 months ago

XOMA Preferred Shares Series A declares $0.5391 dividend

* XOMA Preferred Shares Series A (NASDAQ:XOMAP [https://seekingalpha.com/symbol/XOMAP]) declares $0.5391/share quarterly dividend [https://seekingalpha.com/pr/20239358-xoma-royalty-declares-quarterly-preferred-stock-dividends], in line w... Full story

Yahoo Finance • 2 months ago

XOMA Royalty Declares Quarterly Preferred Stock Dividends

EMERYVILLE, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty’s Series A and Series B Cumulati... Full story

Yahoo Finance • 3 months ago

XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference

EMERYVILLE, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today its Chief Executive Officer, Owen Hughes, and Chief Investment Officer, Brad Sitko, will pres... Full story

Yahoo Finance • 3 months ago

Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share

WALTHAM, Mass. and DUBLIN and EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company (“Mural”), and XOMA Royalty Corporation (Nasdaq: XOMA), a biotechnology royal... Full story

Yahoo Finance • 3 months ago

WALTHAM, DUBLIN, EMERYVILLE - Mural Oncology agrees to acquisition by XOMA Royalty subsidiary

WALTHAM, Mass., DUBLIN, Ireland and EMERYVILLE, Calif. - Mural Oncology plc (NASDAQ:MURA) has entered into a definitive agreement to be acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty Corporation (NASDAQ:XOMA), for bet... Full story

Yahoo Finance • 3 months ago

HILLEVAX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of HilleVax, Inc. - HLVX

NEW YORK CITY and NEW ORLEANS, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of HilleVax, Inc. (Na... Full story

Yahoo Finance • 4 months ago

XOMA earnings beat by $0.64, revenue topped estimates

Investing.com - XOMA (NASDAQ: XOMA) reported second quarter EPS of $0.44, $0.64 better than the analyst estimate of $-0.20. Revenue for the quarter came in at $13.13M versus the consensus estimate of $8.67M. XOMA’s stock price closed at $... Full story

Yahoo Finance • 4 months ago

XOMA GAAP EPS of $0.44 beats by $0.59, revenue of $13.13M beats by $3.74M

* XOMA press release [https://seekingalpha.com/pr/20199201-xoma-royalty-reports-second-quarter-and-year-to-date-2025-financial-results-and-highlights] (NASDAQ:XOMA [https://seekingalpha.com/symbol/XOMA]): Q2 GAAP EPS of $0.44 beats by $0... Full story

Yahoo Finance • 4 months ago

XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements

XOMA Royalty Corporation Business development: Purchased mezagitamab royalty and milestone rights held by BioInvent International and will secure royalty economic interests in two early-stage partnered assets through XOMA Royalty’s recent... Full story

Yahoo Finance • 4 months ago

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: HilleVax, Inc. (Nasdaq – HLVX), Steelcase Inc. (NYSE – SCS), LAVA Therapeutics N.V. (Nasdaq – LVTX), Arcadia Biosciences, Inc. (Nasdaq – RKDA)

BALA CYNWYD, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ack... Full story

Yahoo Finance • 4 months ago

XOMA Royalty to acquire cancer drug developer LAVA Therapeutics

[Wooden blocks with text M and A on light blue paper, business concept. MA - short for mergers and acquisitions] Biotech royalty aggregator XOMA Royalty (NASDAQ:XOMA [https://seekingalpha.com/symbol/XOMA]) has agreed to acquire cancer dru... Full story